Ma Haiching, Deacon Sean, Horiuchi Kurumi
Chief Technology Officer, Reaction Biology Corporation, One Great Valley Parkway, Suite 8, Malvern, PA 19355, USA, Tel: +1 610 722 0247; ; E-mail:
Expert Opin Drug Discov. 2008 Jun;3(6):607-621. doi: 10.1517/17460441.3.6.607.
Protein kinases represent one of the most promising groups of drug targets owing to their involvement in such pathological conditions as cancer, inflammatory diseases, neural disorders, and metabolism problems. In the last few years, numerous pharmaceutical and biotech companies have established kinase high-throughput screening (HTS) programs, and the reagent and service industries for kinase assay platforms, kits, and profiling services have begun to thrive. OBJECTIVE: The plethora of different assay formats available today poses a great challenge to scientists who want to select a technology that will be cost efficient, convenient to use, and have low false positive and false negative rates. METHODS: In the current review, we summarize the most commonly used kinase assay methods in the drug discovery process, present the advantages and disadvantages of each of these methods, and discuss the challenges of discovering kinase inhibitors by using these technologies. CONCLUSIONS: The decision of selecting the assay formats for HTS or service platform for profiling should take into account not only the final goals of the screens but also the limitation of resources.
蛋白激酶因其参与癌症、炎症性疾病、神经紊乱和代谢问题等病理状况,成为最具前景的药物靶点类别之一。在过去几年里,众多制药和生物技术公司已开展激酶高通量筛选(HTS)项目,用于激酶检测平台、试剂盒及分析服务的试剂和服务行业开始蓬勃发展。目的:当今大量不同的检测形式给那些想要选择一种具有成本效益、使用方便且假阳性和假阴性率低的技术的科学家带来了巨大挑战。方法:在本综述中,我们总结了药物发现过程中最常用的激酶检测方法,阐述了每种方法的优缺点,并讨论了使用这些技术发现激酶抑制剂所面临的挑战。结论:选择用于高通量筛选的检测形式或分析服务平台的决策不仅应考虑筛选的最终目标,还应考虑资源的限制。